Pergolide: A Review of its Pharmacological Properties and Therapeutic Potential in Parkinson’s Disease

Drugs

Volumn 39, Issue 3, 1990, Pages 491-506

  Langtry, Heather D ^a   Clissold, Stephen P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR; LEVODOPA; LISURIDE; PERGOLIDE;

CLINICAL ARTICLE; DYSKINESIA; ELECTROCARDIOGRAM; HALLUCINATION; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RHINITIS; VERTIGO;

ANIMAL; HUMAN; PARKINSON DISEASE; PERGOLIDE;

PARKINSONIA;

EID: 0025317247     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199039030-00009     Document Type: Article

References (96)

1. Treatment of Parkinson’s disease with pergolide: a double-blind study
2. Pergolide: long-term use in Parkinson’s disease
3. The effect of a single oral dose of pergolide on intraocular pressure and pupil diameter
4. Inhibition of insulin release from rat pancreatic islets by drugs that are analogues of dopamine
5. 2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats
6. Inhibition of SKF 38393-and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro
7. Reversal of sleep disturbance in Parkinson’s disease by antiparkinsonian therapy: a preliminary study
8. Comparison of dopamine agonists in the treatment of hyper-prolactinemic syndromes: a multicenter study
9. Alterations in brain dopamine receptor function following chronic administration of L-Dopa, bromocriptine or pergolide to rats
10. Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs
11. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetrelin, N-n-propyl-3-(3-hydroxyphenyl) piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors
12. Domperidone
13. Pergolide mesylate inhibits exercise-induced prolactin release in man
14. Cardiovascular effects of pergolide mesylate during dynamic exercise
15. Evaluating the evaluations: or how to weigh the scales of parkinsonian disability
16. One-year trial of pergolide as an adjunct to sinemet in treatment of Parkinson’s disease
17. Double-blind trial of pergolide for Parkinson’s disease
18. Parkinson’s disease: an open label trial of pergolide in patients failing bromocriptine therapy
19. Antiparkinson drugs
20. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia
21. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia
22. Elevation of serum corticosterone concentrations in rats by pergolide and other dopamine agonists
23. Pergolide in Parkinson’s disease
24. Chronic agonist therapy for Parkinson’s disease: A 5-year study of bromocriptine and pergolide
25. Interaction of pergolide with central dopaminergic receptors
26. Etude clinique du pergolide dans la maladie de Parkinson
27. Experience with pergolide mesylate in severe Parkinson’s disease
28. Pergolide in the management of advanced Parkinson’s disease
29. Further characterization of tolerance to the corticosterone-elevating effect of pergolide in rats
30. Development of selective dopamine receptor agonists as novel cardiovascular drugs
31. Parkinsonism: onset, progression, and mortality
32. Pergolide improves motor function in Parkinson’s disease without causing adverse mental effects: a neuropsychological study
33. Biphasic effects of selected dopamine agonists on locomotor activity: differential effects in normotensive and hypertensive rats
34. Pergolide treatment in parkinsonism
35. Controlled trial of pergolide mesylate in Parkinson’s disease and progressive supranuclear palsy
36. Long-term study of pergolide in Parkinson’s disease
37. Parallel double-blind study of pergolide in Parkinson’s disease
38. Pergolide therapy in Parkinson’s disease
39. Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain
40. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas studies with high-definition computerised tomography
41. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma: comparison of the efficacy of pergolide and bromocriptine therapy
42. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson’s, disease
43. Pergolide mesylate therapy in Parkinson disease: report of a 3-month trial in 20 patients
44. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone
45. Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson’s disease
46. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia
47. The pharmacological evaluation of pergolide mesylate as a potential anti-Parkinson agent
48. Double-blind assessment of potential pergolide-induced cardiotoxicity
49. Long-term experience with pergolide therapy of advanced parkinsonism
50. Pergolide in late-stage Parkinson disease
51. Pergolide and lisuride for levodopa-induced oscillations
52. Cardiac effects of pergolide
53. Pergolide, a potent long-acting dopamine-receptor agonist
54. Comparison of pergolide and bromocriptine therapy in parkinsonism
55. Potent 48 hours inhibition of prolactin secretion by pergolide in hyperprolactinaemic women
56. Treatment of hyperprolactinaemic patients with pergolide
57. Does pergolide slow the progression of Parkinson’s disease? A 7-year follow-up study
58. Treatment of advanced Parkinson disease with pergolide
59. Further studies with pergolide in Parkinson disease
60. Comparative efficacy of two dopamine agonists, pergolide and lergotrile, in Parkinson disease
61. Long-term treatment with pergolide: decreased efficacy with time
62. The use of pergolide, a potent dopamine agonist, in Parkinson’s disease
63. Efficacy of pergolide and mesulergine
64. Pergolide and lisuride in advanced Parkinson’s disease
65. Pergolide and lisuride for Parkinson’s disease
66. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson’s disease
67. The use of two new dopamine agonists: pergolide and lisuride in Parkinson’s disease
68. Hallucinations and confusion after pergolide withdrawal
69. Pergolide in the treatment of Parkinson’s disease
70. Erythromelalgia following pergolide administration
71. Amphetamine discrimination: effects of dopamine receptor agonists
72. Pergolide, parlodel crossover study
73. Double-blind controlled study of pergolide mesylate in the treatment of Parkinson’s disease
74. Pergolide mesylate: its effects on circulatory anterior pituitary hormones in man
75. Ocular effects of lergotrile, pergolide and bromocriptine
76. Pergolide in the treatment of Parkinson’s disease
77. Degenerative diseases of the nervous system
78. Dopamine agonists as primary treatment in Parkinson’s disease
79. Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a 5-year follow up
80. Lisuride, a dopamine agonist in the treatment ofearly Parkinson’s disease
81. Local cerebral glucose utilisation in treated and untreated patients with Parkinson’s disease
82. Physiologic disposition of pergolide
83. Alpha-2-adrenoceptor-mediated effects of pergolide
84. Pergolide therapy in Parkinson’s disease: a double-blind, placebo-controlled study
85. Long-term efficacy of pergolide in patients with Parkinson’s disease
86. Dopamine agonist-induced hyperglycemia in rats: structure-activity relationships and mechanisms of action
87. Parkinsonism and on-off fluctuations: long-term effects of pergolide therapy
88. Pergolide therapy for Parkinson’s disease: neurobehavi oral changes
89. Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease
90. Pergolide mesylate and idiopathic Parkinson disease
91. Double-blind placebo-controlled trial of pergolide in idiopathic Parkinson’s disease
92. In vivo regional brain distribution of [Se-75]-pergolide in the rat: effects of various dopamine receptor agonists and antagonists
93. Activation of adenylate cyclase in rat striatum by an ergoline dopamine agonist, pergolide
94. Mesulergine and pergolide in previously untreated Parkinson’s disease